NB
Nascent Biotech Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by HOLDEN LOWELL THOMAS, was filed 13 Oct 2015.
Nascent Biotech Inc.: what insiders have been doing
We have very little insider data for Nascent Biotech Inc. so far: the most recent filing dates from 13 October 2015. With so few records, no pattern can be drawn yet. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
1
Thresholds
n/a
Buy Volume
€804,562
1 ops. · all time
Sell Volume
n/a
n/a
Financial data
as of FY 2024FY ended March 2024 · cache
US$0.00
Analyst consensus
Income statement
EBITDA-US$1.7M
Net income-US$2.1M0.0% margin
Valuation
Beta1.62
Balance sheet & cash
Total debtUS$122.5k
Free Cash Flow-US$1.2M
Profitability & ownership
ROA-854.3%
% insiders21.5%
% institutions0.0%
Last declaration on 13 October 2015
Declarations1 total
- 617,346 shares@ US$1.45Common StockSEC:0001477932-15-006347:0Canonical exit: 3 Dec 2015 (T+90)
1 of 1 declaration
About Nascent Biotech Inc.
Nascent Biotech Inc. is a company focused on developing biological therapies for cancer treatment. It is listed on NASDAQ under the ticker symbol NBIO.
